Anika Therapeutics has reported that total revenue for the second quarter of 2009 showed an increase of 5%, to $9.52 million, from $9.06 million in the second quarter of 2008. Total revenue for the first six months of 2009 increased 6% to $18.72 million, as compared to $17.6 million for the same period in 2008.
Net income for the second quarter of 2009 increased 18% to $956,000, or $0.08 per diluted share, from $813,000, or $0.07 per diluted share, for the same period last year. Net income for the first six months of 2009 increased 3% to $1.47 million, or $0.13 per diluted share, from $1.43 million, or $0.12 per diluted share, for the first six months of 2008.
Charles Sherwood, president and chief executive officer of Anika, said: “We generated steady sequential and year-over-year top-line growth in the second quarter of the year, driven by strong domestic sales of our flagship joint health product, ORTHOVISC. In fact, our commercialization partner, DePuy Mitek, delivered a 34% year-over-year increase in unit growth to a record quarterly level.
“Based on our first-half financial performance and our outlook for the second half of the year, we continue to expect to generate good revenue growth and improved profitability in 2009. Looking further ahead, we are confident that the investments we are making in Anika will result in accelerated growth in 2010 and beyond,” he added.